Advanced search
Publication Cover
Breast Cancer: Targets and Therapy Volume 5, 2013 - Issue
Submit an article Journal homepage
107
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer

Yasser Abdel Kader1 Department of Clinical Oncology, Cairo University, Cairo, Egypt
,
Marc Spielmann2 Department of Medical Oncology, Institute Gustave Rousssy, VuilleJuif, Paris, France
,
Tamer El-Nahas1 Department of Clinical Oncology, Cairo University, Cairo, EgyptCorrespondence[email protected]
,
Amr Sakr1 Department of Clinical Oncology, Cairo University, Cairo, Egypt
&
Hassan Metwally3 Department of Clinical Oncology, Monufia University, Monufia, Egypt
Pages 37-42 | Published online: 17 Jun 2013

Figures & data

Table 1 Baseline patients and disease characteristics for randomly assigned patients

Figure 1 Median TTP in both arms.

Abbreviation: TTP, time to progression.
Figure 1 Median TTP in both arms.

Figure 2 WHO PS correlation with TTP in the whole study group.

Abbreviations: TTP, time to progression; WHO PS, World Health Organization performance status.
Figure 2 WHO PS correlation with TTP in the whole study group.

Figure 3 Steroid hormone correlation with TTP in the whole study group.

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; TTP, time to progression.
Figure 3 Steroid hormone correlation with TTP in the whole study group.

Figure 4 Bone/visceral metastasis correlation with TTP in the whole study group.

Abbreviations: TTP, time to progression; visc, visceral.
Figure 4 Bone/visceral metastasis correlation with TTP in the whole study group.

Figure 5 Bone/visceral metastasis correlation with median OS in the whole study group.

Abbreviation: OS, overall survival; visc, visceral.
Figure 5 Bone/visceral metastasis correlation with median OS in the whole study group.

Figure 6 Median OS in both arms.

Abbreviation: OS, overall survival.
Figure 6 Median OS in both arms.

Figure 7 Age correlation with median OS in the whole study group.

Abbreviation: OS, overall survival.
Figure 7 Age correlation with median OS in the whole study group.

Table 2 Toxicity profile in both treatment arms

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.